Study wrapper · #1066
The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany.
Editor's note
This is a Markov-microsimulation cost-effectiveness model, not a clinical trial; its outputs depend on published transition probabilities and cost inputs. It suggests semaglutide and tirzepatide are associated with modeled gains in kidney-related outcomes and survival, with semaglutide remaining cost-effective and tirzepatide constrained by its higher price. Readers should read the numbers as scenario estimates specific to the German statutory system rather than measured patient outcomes.
Plain-language abstract
A German health-economic simulation modeled adding second-line diabetes drugs to standard care and estimated modest gains in quality-adjusted life years and life expectancy for semaglutide and tirzepatide, at higher cost. Semaglutide and empagliflozin remained cost-effective at the chosen threshold, while tirzepatide's higher cost lowered its net benefit.